CN115028695A - Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof - Google Patents

Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof Download PDF

Info

Publication number
CN115028695A
CN115028695A CN202210568272.6A CN202210568272A CN115028695A CN 115028695 A CN115028695 A CN 115028695A CN 202210568272 A CN202210568272 A CN 202210568272A CN 115028695 A CN115028695 A CN 115028695A
Authority
CN
China
Prior art keywords
seq
ltbi
ala
tuberculosis
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210568272.6A
Other languages
Chinese (zh)
Other versions
CN115028695B (en
Inventor
龚文平
吴雪琼
梁艳
王杰
刘银萍
薛勇
米洁
李鹏川
王小鸥
王兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
8th Medical Center of PLA General Hospital
Original Assignee
8th Medical Center of PLA General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 8th Medical Center of PLA General Hospital filed Critical 8th Medical Center of PLA General Hospital
Priority to CN202210568272.6A priority Critical patent/CN115028695B/en
Priority claimed from CN202210568272.6A external-priority patent/CN115028695B/en
Publication of CN115028695A publication Critical patent/CN115028695A/en
Application granted granted Critical
Publication of CN115028695B publication Critical patent/CN115028695B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The invention discloses a Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof. Particularly discloses the composition of Th1 and CTL epitope peptide pool based on LTBI-RD related protein and the application thereof in the differential diagnosis of active tuberculosis and latent tuberculosis infection. The peptide pool can stimulate ATB, LTBI and UC group mouse models to generate immune response, so that IFN-gamma + The absolute counting level of T lymphocytes and the secretion level of Th1/Th2/Th9/Th17/Th22/Treg related cytokines have obvious difference among three groups, and ATB and LTBI can be well differentially diagnosed. The Th1 and CTL epitope peptide pool are used as ATB and LTBI diagnostic markers, and compared with the traditional detection technologies of TST and IGRAs, the kit has the advantages of simple preparation method, low cost, high yield, higher sensitivity and specificity and the like.

Description

Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof
Technical Field
The invention belongs to the field of immunology, and relates to a Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof. In particular to a Th1 and CTL epitope mixed peptide pool derived from a Mycobacterium tuberculosis (Mycobacterium tuberculosis) LTBI-RD related protein antigen and application thereof in differential diagnosis of active tuberculosis and latent tuberculosis infection.
Background
Tuberculosis (TB) is a chronic infectious disease caused by infection with Mycobacterium Tuberculosis (MTB), and has become one of ten major infectious diseases in humans. Mycobacterium tuberculosis infection is divided into two states, Active Tuberculosis (ATB) and Latent tuberculosis infection (LTBI). Studies have shown that approximately 26% of the world's population is infected with tuberculosis, of which only 10% suffer from active tuberculosis, which means that nearly 90% of people are latent tuberculosis infections (LTBI). LTBI is a special condition in which an individual has been infected with Mycobacterium tuberculosis, but has not developed Active Tuberculosis (ATB), and is characterized by a Tuberculin Skin Test (TST) positive, with no clinical manifestations of ATB and no changes in imaging. It is estimated that LTBI patients have a lifetime risk of developing ATB of 5-10% without timely diagnosis and intervention, which may be up to 10% per year, much higher than HIV-negative populations if they are concurrently infected with Human Immunodeficiency Virus (HIV). Epidemiological investigations have shown that about 85% to 90% of newly developed active tuberculosis develop from LTBI. Therefore, early detection and diagnosis of LTBI patients is the basis for controlling tuberculosis transmission, can reduce the risk of developing active tuberculosis, and can carry out screening and preventive intervention, and becomes an important measure for the target of a global tuberculosis control strategy.
TST is the only means for rapidly diagnosing the potential infection of tubercle bacillus for a long time, but the method has low specificity and brings great difficulty to the diagnosis of tuberculosis. The antigen used in the traditional TST test is Old Tuberculin (OT) or Purified Protein Derivative (PPD), which has partial common antigens with bacillus calmette-guerin (BCG) and other mycobacteria and thus has cross reaction, resulting in high false positive rate of people inoculated with BCG, and the TST test cannot distinguish LTBI from ATB patients. Recently, several new TST detection methods have been developed, such as the Diaskin test, the C-Tb skin test and the EC (recombinant Mycobacterium tuberculosis fusion protein) test, which replace the conventional PPD with Early secretory antigen target 6(Early secreted antigenic target-6, ESAT-6) and Culture filtrate protein10 (CFP-10) antigens of virulent strains of Mycobacterium tuberculosis. With the development of immunological technology, a method for diagnosing tuberculosis based on In vitro interferon gamma release analysis (IFN- γ releasesay, IGRA) has been established, which determines the infection of tubercle bacillus by measuring the amount of IFN- γ produced by T lymphocytes In human peripheral blood after stimulation with a tuberculosis-specific antigen, with stronger specificity and higher sensitivity than the TST method, and five commercial IGRA kits have been developed to overcome the defects of conventional TSTs, such as T cell spot test for tuberculosis detection (T-spot. TB), QuantiFERON TB Gold Tube In Tube (QFT-GIT), QuantiFERON TB Gold Plus (QFT Plus), lision QuantiFERON TB Gold Plus (liason T-Plus), and liason TB/LTBI. Coincidently, both these improved TST methods and the latest IGRAs technologies employ ESAT-6 and CFP-10 as stimulating antigens. These two antigens are not present in BCG strains and most of Nontuberculous mycobacteria (NTM), so that cross reaction is not easy to generate, and the influence of BCG inoculation on tuberculosis diagnosis can be eliminated. However, ESAT-6 and CFP-10 are also present in a few NTM's, such as M.kansasii, M.marinum, M.surgara, M.flavum and M.gastri, and although IGRA methods can be used to detect MTB infection, the sensitivity and specificity still lack stringent "gold standards", and positive IGRA detection cannot distinguish between LTBI and ATB. Therefore, the diagnosis method which has higher sensitivity and specificity and low cost and can accurately identify and distinguish LTBI and ATB is further developed, and LTBI patients are discovered and diagnosed at early stage, thereby having important significance and wide clinical application value for controlling tuberculosis epidemic situation.
Disclosure of Invention
The invention aims to provide a group of mixed peptide pools of Th1 epitope peptide and CTL epitope peptide derived from LTBI-RD antigen and application thereof in differential diagnosis of active tuberculosis and latent tuberculosis infection. The technical problem to be solved is not limited to the technical subject described, and other technical subject not mentioned herein may be clearly understood by those skilled in the art through the following description.
To achieve the above objects, the present invention provides, in a first aspect, a polypeptide composition (i.e., Th1 and CTL epitope peptide pool based on LTBI-RD related protein), which may be any one of:
A1) the polypeptide composition (peptide pool 1) consists of polypeptides with the amino acid sequences of 162-176 th position of SEQ ID No.1, 193-207 th position of SEQ ID No.1, 268-276 th position of SEQ ID No.1 and 378-386 th position of SEQ ID No.1 respectively;
A2) the polypeptide composition (peptide pool 2) consists of polypeptides with amino acid sequences of 95 th to 109 th sites of SEQ ID No.2, 92 th to 106 th sites of SEQ ID No.2, 23 th to 31 th sites of SEQ ID No.2 and 92 th to 100 th sites of SEQ ID No. 2;
A3) the polypeptide composition (peptide pool 3) consists of polypeptides with the amino acid sequences of 42-56 th position of SEQ ID No.3, 128-142 th position of SEQ ID No.3, 133-141 th position of SEQ ID No.3 and 131-139 th position of SEQ ID No. 3;
A4) the polypeptide composition (peptide pool 4) consists of polypeptides with the amino acid sequences of 294-308, 296-310, 202-210 and 325-333 of SEQ ID No.4 respectively;
A5) the polypeptide composition (peptide pool 5) consists of polypeptides with amino acid sequences of 2 th to 16 th positions of SEQ ID No.5, 16 th to 30 th positions of SEQ ID No.5, 47 th to 56 th positions of SEQ ID No.5 and 41 th to 49 th positions of SEQ ID No. 5;
A6) the polypeptide composition (combination of the peptide pool1 and the peptide pool 5) consists of polypeptides with amino acid sequences of 162-176 th position of SEQ ID No.1, 193-207 th position of SEQ ID No.1, 268-276 th position of SEQ ID No.1, 378-386 th position of SEQ ID No.1, 2-16 th position of SEQ ID No.5, 16-30 th position of SEQ ID No.5, 47-56 th position of SEQ ID No.5 and 41-49 th position of SEQ ID No. 5;
A7) the polypeptide composition (combination of peptide pool1, peptide pool 2, peptide pool 3 and peptide pool 4) consists of peptide fragments with amino acid sequences of 162-176 of SEQ ID No.1, 193-207 of SEQ ID No.1, 268-276 of SEQ ID No.1, 378-386 of SEQ ID No.1, 95-109 of SEQ ID No.2, 92-106 of SEQ ID No.2, 23-31 of SEQ ID No.2, 92-100 of SEQ ID No.2, the 42-56 position of the SEQ ID No.3, the 128-142 position of the SEQ ID No.3, the 133-141 position of the SEQ ID No.3, the 131-139 position of the SEQ ID No.3, the 294-308 position of the SEQ ID No.4, the 296-310 position of the SEQ ID No.4, the 202-210 position of the SEQ ID No.4 and the 325-333 position of the SEQ ID No. 4.
Wherein: A1) the amino acid sequence in the sequence is the polypeptide name Th1-Rv1737c-P3 at position 162-176 of SEQ ID No.1, and the amino acid sequence is TTHAIVAAALASTAV; the amino acid sequence is the polypeptide name Th1-Rv1737c-P5 at the 193-207 position of SEQ ID No.1, and the amino acid sequence is DPVLPRLKAAARLPV; the polypeptide with the amino acid sequence of 268-276 of SEQ ID No.1 has the name of CTL-Rv1737c-P1, and the amino acid sequence of RIAPRHVVL; the polypeptide with the amino acid sequence of the 378-386 position of the SEQ ID No.1 is named as CTL-Rv1737c-P2, and the amino acid sequence is CTYTALHAR.
A2) The amino acid sequence is the polypeptide name of 95 Th to 109 Th sites of SEQ ID No.2 is Th1-Rv2031c-P1, and the amino acid sequence is YGSFVRTVSLPVGAD; the amino acid sequence is the polypeptide name of the 92 Th to 106 Th sites of SEQ ID No.2 is Th1-Rv2031c-P2, and the amino acid sequence is EFAYGSFVRTVSLPV; the amino acid sequence is the polypeptide name of 23 rd to 31 th positions of SEQ ID No.2 and is CTL-Rv2031c-P1, and the amino acid sequence is AAFPSFAGL; the polypeptide with the amino acid sequence of 92 th to 100 th positions of SEQ ID No.2 is named as CTL-Rv2031c-P2, and the amino acid sequence is EFAYGSFVR.
A3) The amino acid sequence in the sequence is the polypeptide name Th1-Rv2626c-P1 at the 42 Th to the 56 Th positions of SEQ ID No.3, and the amino acid sequence is DDRLHGMLTDRDIVI; the polypeptide with the amino acid sequence at the 128-142 Th position of SEQ ID No.3 has the name Th1-Rv2626c-P2 and the amino acid sequence IVQFVKAICSPMALA; the polypeptide with the amino acid sequence of the 133-141 th site of the SEQ ID No.3 has the name of CTL-Rv2626c-P1 and the amino acid sequence of KAICSPMAL; the polypeptide with the amino acid sequence of the 131 th-139 nd position of SEQ ID No.3 is named as CTL-Rv2626c-P2, and the amino acid sequence is FVKAICSPM.
A4) The amino acid sequence in the sequence is the polypeptide name Th1-Rv2659c-P1 at the 294-308 Th position of SEQ ID No.4, and the amino acid sequence is PSALYRMFYKARKAA; the polypeptide with the amino acid sequence of the 296-310 Th site of SEQ ID No.4 is named as Th1-Rv2659c-P2, and the amino acid sequence is ALYRMFYKARKAAGR; the polypeptide with the amino acid sequence of position 202-210 of SEQ ID No.4 is named as CTL-Rv2659c-P1, and the amino acid sequence is MAAWLAMRY; the polypeptide with the amino acid sequence of the 325-333 th position of SEQ ID No.4 has the name of CTL-Rv2659c-P2, and the amino acid sequence of LAASTGATL.
A5) The amino acid sequence is the polypeptide name of 2 nd to 16 Th sites of SEQ ID No.5, Th1-Rv2660c-P1, and the amino acid sequence is IAGVDQALAATGQAS; the amino acid sequence is the polypeptide name of 16 Th to 30 Th sites of SEQ ID No.5, Th1-Rv2660c-P2, and the amino acid sequence is SQRAAGASGGVTVGV; the amino acid sequence is the polypeptide name of 47-56 th site of SEQ ID No.5, CTL-Rv2660c-P1, and the amino acid sequence is FTFSSRSPDF; the amino acid sequence is the polypeptide name of 41 th to 49 th positions of SEQ ID No.5, CTL-Rv2660c-P2, and the amino acid sequence is VVAPSQFTF.
The polypeptides CTL-Rv1737c-P1, CTL-Rv1737c-P2, CTL-Rv2031c-P1, CTL-Rv2031c-P2, CTL-Rv2626c-P1, CTL-Rv2626c-P2, CTL-Rv2659c-P1, CTL-Rv2659 c-P35 2, CTL-Rv26 2660c-P1 and CTL-Rv2660c-P2 are CTL epitope peptides of the mycobacterium tuberculosis LTBI-RD related protein antigen; the polypeptides Th1-Rv1737c-P3, Th1-Rv1737c-P5, Th1-Rv2031c-P1, Th1-Rv2031c-P2, Th1-Rv2626c-P1, Th1-Rv2626c-P2, Th1-Rv2659c-P1, Th1-Rv2659c-P2, Th1-Rv2660c-P1 and Th1-Rv2660c-P2 are Th1 epitope peptides of the LTBI-RD related protein antigen of mycobacterium tuberculosis.
The antigen proteins related to the mycobacterium tuberculosis LTBI-RD (antigens belonging to the tuberculosis latent infection related and BCG deletion area at the same time) are Rv1737c, Rv2031c, Rv2626c, Rv2659c and Rv2660 c. The amino acid sequence of the antigen protein Rv1737c is shown as SEQ ID No.1, the amino acid sequence of the antigen protein Rv2031c is shown as SEQ ID No.2, the amino acid sequence of the antigen protein Rv2626c is shown as SEQ ID No.3, the amino acid sequence of the antigen protein Rv26 2659c is shown as SEQ ID No.4, and the amino acid sequence of the antigen protein Rv2660c is shown as SEQ ID No. 5.
The invention also provides any one of the following applications of the polypeptide composition:
B1) use in the diagnosis and/or identification of diseases caused by mycobacterium tuberculosis;
B2) use in the manufacture of a product for the diagnosis and/or identification of diseases caused by mycobacterium tuberculosis;
B3) the application in distinguishing active tuberculosis patients and latent tuberculosis infected patients;
B4) the application in preparing products for distinguishing active tuberculosis patients and latent tuberculosis infectors;
B5) the application in diagnosing latent tuberculosis infection or preparing products for diagnosing latent tuberculosis infection;
B6) use in the identification of healthy subjects and patients with active tuberculosis;
B7) use in the manufacture of a product for the differential discrimination between healthy subjects and patients with active tuberculosis;
B8) the application in distinguishing healthy subjects from latent tuberculosis infected persons;
B9) the application in preparing products for distinguishing healthy subjects from latent tuberculosis infected persons;
B10) application in preparing tuberculosis vaccine.
In the above use, the disease caused by Mycobacterium Tuberculosis (MTB) may be Tuberculosis (TB).
In the above application, the tuberculosis may be Active Tuberculosis (ATB) or Latent tuberculosis infection (LTBI).
The invention also provides a kit for identifying active tuberculosis and latent tuberculosis infection, wherein the kit comprises any one of the polypeptide compositions described in the text.
In the kit, the kit further comprises an IFN-gamma detection reagent.
Herein, the product may be a reagent, a kit (e.g., a diagnostic kit), or a medicament.
Further, the active ingredient of the product is a mixed peptide pool consisting of Th1 epitope peptide derived from LTBI-RD antigen and CTL epitope peptide.
The Th1 epitope peptide and CTL epitope peptide in the mixed peptide pool can be artificially synthesized by conventional techniques.
The disease caused by mycobacterium tuberculosis described herein may be a human disease caused by mycobacterium tuberculosis or a mouse disease caused by mycobacterium tuberculosis, but is not limited thereto.
The invention also provides a biomarker for differential diagnosis of active tuberculosis and latent tuberculosis infection, wherein the biomarker can be the peptide pool1, the peptide pool 2, the peptide pool 3, the peptide pool 4, the peptide pool 5 or the combination of the peptide pool1 and the peptide pool 5 or the combination of the peptide pool1, the peptide pool 2, the peptide pool 3 and the peptide pool 4.
The present invention also provides a method of identifying a latent tuberculosis infection from an active tuberculosis infection, the method comprising:
C1) co-culturing a sample of the subject with a stimulus, which can be peptide pool1, peptide pool 2, peptide pool 3, peptide pool 4, or peptide pool 5, or a combination of peptide pool1 and peptide pool 5, or a combination of peptide pool1, peptide pool 2, peptide pool 3, and peptide pool 4;
C2) detecting the level of secreted IFN-gamma in the sample, and distinguishing active tuberculosis infection from latent tuberculosis infection according to the IFN-gamma level.
The level of secreted IFN-gamma in the test sample is determined by measuring the stimulation of the peptide pool
Figure BDA0003659180790000041
The number of cells of (a).
Further, the level of secreted IFN- γ in the test sample can be determined by
Figure BDA0003659180790000042
The ELISPOT kit of (1) to detect stimulation by the polypeptide
Figure BDA0003659180790000043
The number of cells of (a).
The subject sample described herein can be a blood sample or a tissue sample.
The above uses and methods may be for disease diagnosis purposes, disease prognosis purposes and/or disease treatment purposes, or they may be for non-disease diagnosis purposes, non-disease prognosis purposes and non-disease treatment purposes; their direct purpose may be to obtain information on the outcome of a disease diagnosis, prognosis of a disease and/or intermediate outcome of a disease treatment, and their direct purpose may be non-disease diagnosis, non-disease prognosis and/or non-disease treatment.
The invention takes five antigen proteins (Rv1737c, Rv2031c, Rv2626c, Rv2659c and Rv2660c) as target antigens, and predicts potential epitopes recognized by type I helper T cells (Th1) and cytotoxic T Cells (CTL) by using a bioinformatics technology. In vitro synthesis of predicted dominant Th1 epitope peptide and CTL epitope peptide, mixing LTBI-RD antigen-derived Th1 epitope peptide and CTL epitope peptide to construct peptide pool, and evaluating potential ability of LTBI and ATB in animal model by enzyme-linked immunospot assay (ELISPOT) and high-throughput liquid protein microarray detection technology. In addition, sensitivity and specificity of these peptide pools were determined using a receiver-operator characteristic (ROC) curve. The invention provides a new differential diagnosis candidate target for the differential diagnosis of LTBI and ATB, and emphasizes the potential value of LTBI-RD antigen-derived peptides as a new method for diagnosing LTBI and ATB.
The invention discovers for the first time that 5 peptide pools (Pool 1-Pool 5) consisting of Th1 epitope peptide and CTL epitope peptide of mycobacterium tuberculosis can stimulate ATB, LTBI and Uninfected Control (UC) BALB/c mouse models to generate immune response, so that IFN-gamma + T showerThe absolute counting level of the blast cells and the secretion level of Th1/Th2/Th9/Th17/Th22/Treg related cytokines have obvious difference among three groups, and ATB and LTBI can be well differentially diagnosed on a mouse model. Th1 and CTL epitope peptides constituting the 5 peptide pools were artificially prepared by a polypeptide synthesis technique. Compared with the traditional detection technologies TST and IGRAs, the mixed peptide pool is used as the biomarker for differential diagnosis of ATB and LTBI, and has the advantages of simple preparation method, low cost, high yield, higher sensitivity and specificity and the like. The invention has great value for the diagnosis or differential diagnosis of active tuberculosis and latent tuberculosis infection.
Drawings
FIG. 1 is a flow chart of ATB and LTBI animal model construction.
FIG. 2 is an evaluation of ATB and LTBI mouse models. After 4 weeks of infection of mice in ATB and LTBI groups with Mycobacterium tuberculosis, LTBI groups were given isoniazid and pyrazinamide treatments for 12 weeks. Survival of each group of mice was observed and recorded (a in fig. 2). After week 29, three groups of mice were sacrificed and lung weights (B in fig. 2) and CFU (C in fig. 2) were analyzed. Then, the right lung lobes of each group of mice were HE-stained and observed under a microscope at an original magnification of 40 (D in fig. 2). Each group was displayed with 2 representative images (D in fig. 2), and the lesion area of each mouse was observed and counted by software (E in fig. 2). Data are presented as Mean + -SEM and compared using one-way variance analysis (ANOVA) or Kruskal-Wallis test based on the normality and homogeneity of variance of the data. P <0.05 is a significant difference.
FIG. 3 shows the induction of IFN-. gamma.in mice by 5 peptide pools + And (4) detecting the number of T lymphocytes. 5 pools of mixed peptides were used to stimulate splenocytes in mice in the ATB, LTBI or UC groups in vitro. Each 3X 10 of the assays were performed using the mouse ELISPOT kit 5 IFN-gamma in cells + T lymphocyte count (expressed as SFC). The results were statistically analyzed by Kruskal-Wallis test or one-way analysis of variance (ANOVA) based on the normality and homogeneity of variances. Data are expressed as mean + SEM (n ═ 3), P<A difference of 0.05 is statistically significant.
FIG. 4 is a graph of peptide pool induced IFN-. gamma.for ATB, LTBI and UC mice + ROC curve of T lymphocytes. Detection of IFN-. gamma.induced by 5 peptide pools by ROC Curve using Wilson/Brown assay + Sensitivity and specificity of T lymphocytes to ATB, LTBI and UC diagnosis. AUC and P values are shown in each figure. P<The difference was significant at 0.05.
FIG. 5 is a schematic diagram showing the dilution of the standard in example 6.
FIG. 6 is a peptide pool induced cytokine study. Splenocytes from mice in groups ATB, LTBI and UC were taken and stimulated with 5 peptide pools for 48 hours. And (2) detecting the cytokine levels of IFN-gamma, IL-12p70, IL-13, IL-1 beta, IL-2, IL-4, IL-5, IL-6, TNF-alpha, GM-CSF, IL-18, IL-10, L-17A, IL-22, IL-23, IL-27 and IL-9 in the supernatant by using a mouse Th1/Th2/Th9/Th17/Th22/Treg cytokine kit. Cytokine differences were compared for each group using Tukey test modified two-way analysis of variance (ANOVA). P values for cytokine differences (ATB vs LTBI, ATB vs UC, LTBI vs UC) for each group are shown in the heatmap (a in fig. 6). The significant difference is represented by a light grey box with a P value <0.05, and a dark grey box with a P value ≧ 0.05. In addition, P values of the polypeptide-induced cytokines between the ATB group and LTBI group, the ATB group and UC group, and the LTBI group and UC group were less than 0.05, which are represented by white diagonal grids, and detailed information is represented by violin diagram (B in fig. 6).
FIG. 7 is a ROC curve for peptide pool induced cytokines in the identification of ATB, LTBI and UC mice. The sensitivity and specificity of IFN-. gamma.and IL-6 cytokines induced by the 5 peptide pools to ATB, LTBI and UC diagnosis was determined by ROC curves using Wilson/Brown assay. AUC and P values are shown in each figure. P <0.05 was significantly different.
Detailed Description
The present invention is described in further detail below with reference to specific embodiments, and the examples are given only for illustrating the present invention and not for limiting the scope of the present invention. The examples provided below serve as a guide for further modifications by a person skilled in the art and do not constitute a limitation of the invention in any way.
The experimental procedures in the following examples, unless otherwise indicated, are conventional and are carried out according to the techniques or conditions described in the literature in the field or according to the instructions of the products. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
In the quantitative tests in the following examples, three replicates were set up and the results averaged.
Wild-type BALB/c mice (6-7 weeks old, female) in the examples described below were the product of experimental animal technology, Inc., of Weitongli, Beijing (www.vitalriver.com).
All epitope peptides in the following examples were synthesized by Hangzhou Dangang Biotechnology Ltd.
The Roche medium (product name: Roche tube (acidic)) in the following examples is a product of Bessel Biotechnology, Inc. (Baso Biotechnology Co., LTD, Zhuhaii, Guangdong provision, China) under the product number BA 7005E.
Gibco in the following examples TM The culture medium of the Advanced RPMI 1640 is a product of Saimeri Fei Chinese Limited, the product number is 12633012, and the culture medium is simply called the culture medium of the Advanced RPMI 1640.
Mouse IFN-. gamma.ELISpot in the examples PLUS kit (ALP) is a product of MABTECH, Sweden, cat # 3321-4 APT-2.
Th1/Th2/Th9/Th17/Th22/Treg Cytokine 17-Plex Mouse procapraplex in the following examples TM Panel is a product of Saimei Fei China Co., Ltd., product number EPX 170-26087-.
The Chinese population dominant HLA molecular sieves in the examples below were selected from the Allle Frequency Net Database (AFND) (http:// www.allelefrequencies.net/default. asp).
Prediction of Th1 epitopes and CTL epitopes in the following examples utilize an online epitope prediction website: immune Epitope Database (IEDB) Database (http:// tools. IEDB. org/mhcii/or http:// tools. immuneotipe. org/mhci /) was predicted.
The Mycobacterium tuberculosis (Mycobacterium tuberculosis) used in the following examples are all Mycobacterium tuberculosis standard strains H37Rv (Mycobacterium tuberculosis, H37Rv strain) and have been reported in the literature "Yan L, Xiaoyan Z, Li X, et al. immunological and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis [ J ]. Current Gene Therapy, 2016, 16(4): 249-.
Example 1 Chinese population specific HLA I and HLA II allele Screen
1. Enter the Allle Frequency Net Database, select the HLA Allle Frequency Classical submenu. The parameters are selected from Country: China, Sample size ≥ 100(HLA II) or ≥ 500(HLA I), and the other parameters are selected from default values.
2. Click the Search button to start the Search. From the search results, Allles with Allle Frequency of 0.10 (critical value of 0.10 please refer to Paul S, Lindestem Arlehamn C S, Scriba T J, et al. development and evaluation of a broad scheme for prediction of HLA class II restricted T cell epitopes [ J ]. Journal of Immunological Methods 2014,422:733-738.) were selected as dominant HLA I and HLA II restrictive alleles in Chinese population.
3. By searching an Allle Frequency Net Database, selecting Allles with Allle Frequency ue being more than or equal to 0.10 from the search results as the superior HLA I restrictive alleles of the Chinese population, and finally screening 5 superior HLA-A alleles of the Chinese population, wherein the 5 superior HLA-A alleles are HLA-A11: 01, HLA-A02: 01, HLA-A24: 02, HLA-A33: 03 and HLA-A30: 01 respectively; a total of 3 HLA-B alleles, HLA-B15: 01, HLA-B15: 02 and HLA-B15: 11; the total number of HLA-C alleles is 4, and HLA-C01: 02, HLA-C07: 02, HLA-C03: 04, and HLA-C06: 02. Finally, 13 dominant DRB1 alleles in the Chinese population are screened, wherein the 13 dominant DRB1 alleles are respectively H LA-DRB 1: 12, HLA-DRB 1: 09, HLA-DRB 1: 14, HLA-DRB 1: 07, HLA-DRB 1: 15, HLA-DRB 1: 15, HLA-DRB 1: 15, HLA-DRB 1: 16, HLA-DRB 1: 14, HLA-DRB 3:01, HLA-DRB 3:02, HLA-DRB 4:01 and HLA-DRB 5: 01; a total of 8 DQA1/DQB1 alleles, HLA-DQA 1: 05/01/DQB 1:02, LA-DQA 1: 05:01/DQB 1:01, HLA-DQA 1: 03:01/DQB 1: 03:02, HLA-DQA 1:01/DQB 1: 05:01, HLA-DQA 1:01/DQB 1: 06:02, HLA-DQA 1:01/DQB 1: 05:02, HLA-DQA 1:01/DQB 1:03, and HLA-DQA 1:01/DQB 1: 06:01/DQB 1; the total of 4 DPA1/DPB1 alleles were HLA-DPA 1x 01:03/DPB 1x 02:01, HLA-DPA 1x 01/DPB 1x 04:01, HLA-DPA 1x 03:01/DPB 1x 04:02 and HLA-DPA 1x 02:01/DPB 1x 05: 01.
Example 2 prediction and screening of Th1 and CTL epitopes of LTBI-RD associated antigens specific to Chinese population
In previous studies by the Applicant (Gong W and Wu X, (2021), Differential Diagnosis of tension tube Infection and Active tube Infection: A Key to a Successful tube Control strategy, front. Microbiol.12:745592.doi: 10.3389/fmcb.2021.745592), 21 candidate antigens associated with LTBI-RD (antigens belonging to both the Latent Infection of Tuberculosis and the deletion region of BCG) have been identified. In the present invention, five antigens (Rv1737c, Rv2031c, Rv2626c, Rv2659c and Rv2660c) were selected as target antigens from among the 21 candidate antigens, and potential epitopes recognized by type I helper T cells (Th1) and cytotoxic T Cells (CTLs) were predicted using bioinformatics techniques. The amino acid sequence of the antigen protein Rv1737c is shown as SEQ ID No.1, the amino acid sequence of the antigen protein Rv2031c is shown as SEQ ID No.2, the amino acid sequence of the antigen protein Rv2626c is shown as SEQ ID No.3, the amino acid sequence of the antigen protein Rv2659c is shown as SEQ ID No.4, and the amino acid sequence of the antigen protein Rv2660c is shown as SEQ ID No. 5.
1. The amino acid sequences of target proteins such as Rv1737c, Rv2031c, Rv2626c, Rv2659c and Rv2660c are obtained from NCBI databases to predict epitope conditions.
TABLE 1 List of selected RD-LTBI related antigen profiles
Figure BDA0003659180790000071
2. Entering an IEDB database to predict the dominant Th1 and CTL epitope of Chinese population. For Th1 epitope, comprehensive prediction was performed using seven methods such as IEDB recormmed, Consenssus method, Combinatorial library, NN-align (netMHCII-2.2), SMM-align (netMHCII-1.1), Sturniolo and NetMHCIIpan. For CTL epitopes, there are 9 prediction methods in the IEDB database, namely, respectively, Artificial Neural Network (ANN), Stabilized Matrix Method (SMM), SMM with a Peptide, MHC Binding Energy Covariance matrix (SMMPMBEC), scanning matrix derived from Combinatorial Peptide Libraries (Comblib _ Sidney2008), Consense, NetMHCpan, NetMHCcs, PickPocket and NetMHCspan. The system selects the IEDB recommended2.19 method for prediction by default, the method preferentially uses the Consensuss, ANN, SMM, CombLibif and the like for prediction, and the NetMHCIIpan method is adopted when the condition does not allow. The priorities of the methods are respectively Consensus > ANN > SMM > NetMHCpan > CombLib from high to low.
3. The epitopes predicted by the IEDB database were ranked from small to large with a composite score Percentile rank (smaller scores indicate higher affinity). Selecting epitopes with Percentile _ rank score less than or equal to 10 from each target protein epitope as candidate epitopes to obtain 70 Th1 candidate epitopes, wherein Rv1737c, Rv2031c, Rv2626c, Rv2659c and Rv2626c respectively contain 20, 13, 14, 17 and 6 candidate epitopes, and specific epitope information is shown in Table 2.
TABLE 2 IEDB database prediction of dominant Th1 epitope results for LTBI-RD associated antigen sources
Figure BDA0003659180790000081
Figure BDA0003659180790000091
Figure BDA0003659180790000101
4. The epitopes predicted by the IEDB database were ranked from small to large with a composite score Percentile rank (smaller scores indicate higher affinity). Selecting epitopes with Percentile _ rank score less than or equal to 10 from each target protein epitope as candidate epitopes to obtain 70 candidate epitopes, wherein Rv1737c, Rv2031c, Rv2626c, Rv2659c and Rv2626c respectively contain 20, 13, 14, 17 and 6 candidate epitopes, and specific epitope information is shown in Table 3.
TABLE 3 IEDB database prediction of dominant CTL epitope results for LTBI-RD associated antigen sources
Figure BDA0003659180790000102
Figure BDA0003659180790000111
Figure BDA0003659180790000121
5. The predicted dominant Th1 and CTL epitope peptides were synthesized in vitro by Hangzhou Dangang Biotechnology, Inc. by solid phase synthesis, and then purified by high pressure liquid chromatography to prepare purified dominant epitope peptides. The top two epitope peptides were synthesized for each antigen, and were followed to the next if not. Finally synthesizing 10 LTBI-RD related Th1 epitope peptides which are Th1-Rv1737c-P3, Th1-Rv1737c-P5, Th1-Rv2031c-P1, Th1-Rv2031c-P2, Th1-Rv2626c-P1, Th1-Rv2626c-P2, Th1-Rv2659c-P1, Th1-Rv26 2659c-P2, Th1-Rv2660c-P1 and Th1-Rv26 2660 c-P2; and 10 LTBI-RD related CTL epitope peptides which are CTL-Rv1737c-P1, CTL-Rv1737c-P2, CTL-Rv2031c-P1, CTL-Rv2031c-P2, CTL-Rv2626c-P1, CTL-Rv2626c-P2, CTL-Rv2659c-P1, CTL-Rv2659c-P2, CTL-Rv2660c-P1 and CTL-Rv2660c-P2 respectively.
Specifically, the amino acid sequences of 10 LTBI-RD related Th1 epitope peptides are as follows:
the amino acid sequence of the Th1 epitope peptide Th1-Rv1737c-P3 is shown in the 162-176 position (TTHAIVAAALASTAV) of SEQ ID No. 1.
The amino acid sequence of the Th1 epitope peptide Th1-Rv1737c-P5 is shown in the 193-207 (DPVLPRLKAAARLPV) of SEQ ID No. 1.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2031c-P1 is shown in the 95 Th-109 Th position (YGSFVRTVSLPVGAD) of SEQ ID No. 2.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2031c-P2 is shown in 92-106 (EFAYGSFVRTVSLPV) of SEQ ID No. 2.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2626c-P1 is shown in 42-56 (DDRLHGMLTDRDIVI) of SEQ ID No. 3.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2626c-P2 is shown in the 128-position and 142-position (IVQFVKAICSPMALA) of SEQ ID No. 3.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2659c-P1 is shown in 294-308 (PSALYRMFYKARKAA) of SEQ ID No. 4.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2659c-P2 is shown in 296-310 (ALYRMFYKARKAAGR) of SEQ ID No. 4.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2660c-P1 is shown in the 2 nd to 16 Th position (IAGVDQALAATGQAS) of SEQ ID No. 5.
The amino acid sequence of the Th1 epitope peptide Th1-Rv2660c-P2 is shown as 16 Th-30 Th (SQRAAGASGGVTVGV) of SEQ ID No. 5.
The amino acid sequences of 10 LTBI-RD related CTL epitope peptides are as follows:
the amino acid sequence of the CTL epitope peptide CTL-Rv1737c-P1 is shown as 268-276 (RIAPRHVVL) of SEQ ID No. 1.
The amino acid sequence of the CTL epitope peptide CTL-Rv1737c-P2 is shown as position 378-386 (CTYTALHAR) of SEQ ID No. 1.
The amino acid sequence of CTL epitope peptide CTL-Rv2031c-P1 is shown as 23-31 (AAFPSFAGL) of SEQ ID No. 2.
The amino acid sequence of CTL epitope peptide CTL-Rv2031c-P2 is shown as 92-100 (EFAYGSFVR) of SEQ ID No. 2.
The amino acid sequence of the CTL epitope peptide CTL-Rv2626c-P1 is shown as position 133-141 (KAICSPMAL) of SEQ ID No. 3.
The amino acid sequence of the CTL epitope peptide CTL-Rv2626c-P2 is shown as 131-139 th site (FVKAICSPM) of SEQ ID No. 3.
The amino acid sequence of the CTL epitope peptide CTL-Rv2659c-P1 is shown as position 202-210 (MAAWLAMRY) of SEQ ID No. 4.
The amino acid sequence of the CTL epitope peptide CTL-Rv2659c-P2 is shown as position 325-333 (LAASTGATL) of SEQ ID No. 4.
The amino acid sequence of the CTL epitope peptide CTL-Rv2660c-P1 is shown as 47 th to 56 th (FTFSSRSPDF) of SEQ ID No. 5.
The amino acid sequence of the CTL epitope peptide CTL-Rv2660c-P2 is shown as 41-49 (VVAPSQFTF) of SEQ ID No. 5.
Example 3 preparation of Th1 and CTL epitope peptide pools based on LTBI-RD related proteins
The 10 Th1 epitope peptides and 10 CTL epitope peptides screened in example 2 were combined into five polypeptide compositions (i.e., 5 peptide pools) as follows:
polypeptide composition 1 (peptide Pool1, Pool 1): consists of Th1 epitope peptide Th1-Rv1737c-P3, Th1-Rv1737c-P5, CTL epitope peptide CTL-Rv1737c-P1 and CTL-Rv1737 c-P2;
polypeptide composition 2 (peptide Pool 2, Pool 2): the epitope peptide of the compound is composed of Th1 epitope peptides Th1-Rv2031c-P1 and Th1-Rv2031c-P2, CTL epitope peptides CTL-Rv2031c-P1 and CTL-Rv2031 c-P2;
polypeptide composition 3 (peptide Pool 3, Pool 3): the epitope peptide of the compound is composed of Th1 epitope peptides Th1-Rv2626c-P1 and Th1-Rv2626c-P2, and CTL epitope peptides CTL-Rv2626c-P1 and CTL-Rv2626 c-P2;
polypeptide composition 4 (peptide Pool 4, Pool 4): consists of Th1 epitope peptides Th1-Rv2659c-P1 and Th1-Rv2659c-P2, and CTL epitope peptides CTL-Rv2659c-P1 and CTL-Rv2659 c-P2;
polypeptide composition 5 (peptide Pool 5, Pool 5): consists of Th1 epitope peptides Th1-Rv2660c-P1 and Th1-Rv2660c-P2, and CTL epitope peptides CTL-Rv2660c-P1 and CTL-Rv2660 c-P2.
Specifically, the method comprises the following steps:
polypeptide composition 1 (peptide Pool1, Pool 1): consists of 4 epitope polypeptides (epitope peptides for short) with the amino acid sequences of 162-176 th position of SEQ ID No.1, 193-207 th position of SEQ ID No.1, 268-276 th position of SEQ ID No.1 and 378-386 th position of SEQ ID No.1 respectively;
polypeptide composition 2 (peptide Pool 2, Pool 2): consists of 4 epitope polypeptides with amino acid sequences of 95 th to 109 th sites of SEQ ID No.2, 92 th to 106 th sites of SEQ ID No.2, 23 th to 31 th sites of SEQ ID No.2 and 92 th to 100 th sites of SEQ ID No. 2;
polypeptide composition 3 (peptide Pool 3, Pool 3): consists of 4 epitope polypeptides with the amino acid sequences of 42-56 th position of SEQ ID No.3, 128-142 th position of SEQ ID No.3, 133-141 th position of SEQ ID No.3 and 131-139 th position of SEQ ID No. 3;
polypeptide composition 4 (peptide Pool 4, Pool 4): consists of 4 epitope polypeptides with the amino acid sequences of 294-308 th site of SEQ ID No.4, 296-310 th site of SEQ ID No.4, 202-210 th site of SEQ ID No.4 and 325-333 th site of SEQ ID No. 4;
polypeptide composition 5 (peptide Pool 5, Pool 5): consists of 4 epitope polypeptides with amino acid sequences of 2 nd to 16 th of SEQ ID No.5, 16 th to 30 th of SEQ ID No.5, 47 th to 56 th of SEQ ID No.5 and 41 th to 49 th of SEQ ID No. 5.
The preparation method of the 5 peptide pools comprises the following steps: the polypeptide solutions of the components were mixed according to the composition of the peptide pool 1-peptide pool 5, X. mu.L of Y mg/mL epitope peptide solution was added to an EP tube and mixed (4 epitope peptides of the same protein), and the total volume was measured using a medium (Gibco) TM Advanced RPMI 1640 medium) to 2mL, i.e., a peptide pool prepared such that the working concentration of each epitope peptide (the content of each epitope peptide) was 100. mu.g/mL. Calculating the formula: x (μ L) ═ 2mL × 0.1mg/mL ÷ Y mg/mL]×1000＝200/Y。
The preparation method comprises the following steps:
peptide pool 1: respectively taking 50 mul of Th1 epitope peptide Th1-Rv1737c-P3 solution, Th1 epitope peptide Th1-Rv1737c-P5 solution, CTL epitope peptide CTL-Rv1737c-P1 solution and CTL epitope peptide CTL-Rv1737c-P2 solution with the concentration of 4mg/mL, adding the mixture into an EP tube, mixing, ensuring that the total volume is 200 mul after mixing, and using Gibco TM The Advanced RPMI 1640 medium was replenished to 2mL, i.e., a peptide pool1 configured with a working concentration of 100. mu.g/mL of each epitope peptide.
Peptide pool 2: 50 μ L of Th1 epitope peptide Th1-Rv2031c-P1 solution, Th1 epitope peptide Th1-Rv2031c-P2 solution, CTL epitope peptide CTL-Rv2031c-P1 solution and CTL epitope peptide CTL-Rv2031c-P2 solution with concentration of 4mg/mL are respectively added into an EP tube to be mixed, the total volume is 200 μ L after mixing, and Gibco is used TM Advanced RPMI 1640 culture medium supplementThe pool was made up to 2mL, i.e., peptide pool 2 configured to have a working concentration of 100. mu.g/mL of each epitope peptide.
Peptide pool 3: adding 50 μ L of Th1 epitope peptide Th1-Rv2626c-P1 solution, Th1 epitope peptide Th1-Rv2626c-P2 solution, CTL epitope peptide CTL-Rv2626c-P1 solution and CTL epitope peptide CTL-Rv2626c-P2 solution with concentration of 4mg/mL into an EP tube, mixing, and adding Gibco to obtain a total volume of 200 μ L TM The Advanced RPMI 1640 medium was replenished to 2mL, i.e., a peptide pool 3 configured with a working concentration of 100. mu.g/mL of each epitope peptide.
Peptide pool 4: 50 μ L of Th1 epitope peptide Th1-Rv2659c-P1 solution, Th1 epitope peptide Th1-Rv2659c-P2 solution, CTL epitope peptide CTL-Rv2659c-P1 solution and CTL epitope peptide CTL-Rv2659c-P2 solution with concentration of 4mg/mL are respectively added into an EP tube to be mixed, the total volume is 200 μ L after mixing, and Gibco is used TM The Advanced RPMI 1640 medium was replenished to 2mL, i.e., a peptide pool 4 configured with a working concentration of 100. mu.g/mL of each epitope peptide.
Peptide pool 5: adding 50 μ L of Th1 epitope peptide Th1-Rv2660c-P1 solution, Th1 epitope peptide Th1-Rv2660c-P2 solution, CTL epitope peptide CTL-Rv2660c-P1 solution and CTL epitope peptide CTL-Rv2660c-P2 solution with concentration of 4mg/mL into an EP tube, mixing, and adding Gibco to obtain mixture with total volume of 200 μ L TM The Advanced RPMI 1640 medium was replenished to 2mL, i.e., a peptide pool 5 configured with a working concentration of 100. mu.g/mL of each epitope peptide.
Example 4 ATB and LTBI mouse model construction
1. Grouping mice: 30 female BALB/c mice, 6-7 weeks old, were stratified by body weight, and randomized into 3 groups (ATB, LTBI and control UC) of 10 mice each, each group having body weights as close as possible.
2. Intervention measures are as follows: as shown in FIG. 1, the ATB and LTBI groups were injected with 0.4mL H37Rv M.tuberculosis suspension per mouse tail vein at a dose of 3.6X 10 5 And (4) CUF. From week 4 to week 17, the LTBI group mice each drunk drinking water containing 0.12g/L isoniazid and 8g/L pyrazinamide, and from week 17 to week 29, the LTBI group mice were given normal drinking water (drinking water without 0.12g/L isoniazid and 8g/L pyrazinamide). Is not infectedControl (UCs) mice were negative controls, fed normally, given normal drinking water, and did not undergo any intervention. The ATB group was fed normally after injection of H37Rv M.tuberculosis suspension and given normal drinking water.
3. And (3) evaluation of a model: after week 29, each group of mice was sacrificed and spleen and lungs were taken to observe the infection model. Briefly, the lungs were weighed and the left lobe of the lung was homogenized in saline. Subsequently, 0.1mL of each lung specimen diluted solution was inoculated into Roche medium, double inoculated, and incubated at 37 ℃. After 28 days, CFU counts were performed for each plate. In addition, pathology was analyzed using the right lung. Lesion area rates were calculated using Image-Pro Plus software (Version 6.0, Media Cybernetics, Inc: Bethesda, MD, USA). The flow chart of infection, treatment, activation and evaluation of the animal model is shown in figure 1.
4. The experimental results are as follows: the results showed that 8 mice in the ATB group died after infection with M.tuberculosis, while mice in the LTBI and UC groups survived. The survival rate of the ATB group was significantly lower than that of the LTBI and UC groups (P ═ 0.0003, a in fig. 2). The lung weight (P ═ 0.0032, B in fig. 2) and CFU load (P ═ 0.0007, C in fig. 2) were significantly higher in the ATB group of mice than in the UC group. Although the lung weights and CFU loads of LTBI group mice were statistically not statistically different from those of the ATB and UC groups, we found that the mean values of lung weights and CFU loads of LTBI group mice were higher than those of the UC group and much lower than those of the ATB group (B in fig. 2 and C in fig. 2). Lung lesions were observed in groups of mice under 40-fold visual field (D in fig. 2), and statistics showed that lung lesion areas were significantly larger in the ATB group (P <0.0001) and UC group (P <0.0001), and significantly larger in the LTBI group (P <0.0001, E in fig. 2). These data indicate that the ATB and LTBI mouse models have been successfully constructed, resulting in ATB model mice, LTBI model mice and control mice.
Example 5 ELISPOT experiments on ATB and LTBI mouse models
30 female BALB/c mice 6-7 weeks old and 16-18g in weight were randomly divided into 3 groups (ATB group, LTBI group and control UC group) of 10 mice each according to the method of example 4, and ATB model mice, LTBI model mice and control mice were constructed according to the method of example 4.
This example uses Mouse IFN-. gamma.ELISpot PLUS kit (ALP) an IFN- γ ELISPOT assay was performed to test the 5 peptide pools of example 3 for their ability to induce secretion of IFN- γ by T cells. The method comprises the following specific steps:
1. preparation of spleen cell suspension: the mice were sacrificed and were sterilized in 75% alcohol for 10min before being removed, and the spleens were dissected and removed. 10mL of Advanced RPMI 1640 was pipetted into a sterile petri dish, a sterile 200 mesh copper mesh was placed in the petri dish, the spleen was then placed on the 200 mesh copper mesh, and the spleen cells were spread by gentle squeezing with the syringe plunger tip (sterile). An ELISOT plate (Mouse IFN-. gamma.ELISpot) was prepared in advance PLUS kit (ALP) components): PBS washed four times (200. mu.L/well), and then incubated with Advanced RPMI 1640 medium containing 10% Fetal Bovine Serum (FBS) at 200. mu.L/well for at least 30min to give a spleen cell suspension.
2. And (3) red blood cell lysis: the spleen cell suspension obtained above was centrifuged at 500g at 4 ℃ for 5min, and the supernatant was discarded. Adding erythrocyte lysate in an amount of 20-30 mL/spleen, gently blowing, mixing, and lysing at room temperature for 4-5 min. During which time it was gently shaken every minute. Centrifuge at 500g for 5min at 4 ℃ and discard the red supernatant. If the lysis of the erythrocytes is found to be incomplete, the above procedure can be repeated once. Usually, the trace amount of red blood cells does not affect some of the subsequent tests. Washing for 1-2 times: adding appropriate amount of Advanced RPMI 1640 culture medium, resuspending the precipitate, centrifuging at 4 deg.C and 500g for 2-3min, and discarding the supernatant. Repeating for 1 more times, and washing for 1-2 times to obtain lymphocyte precipitate. The amount of washing solution used should generally be at least 5 times the volume of the cell pellet.
3. Counting and paving: resuspending the lymphocyte pellet in Advanced RPMI 1640 medium, counting the cells, adjusting the cell concentration to 3X 10 6 one/mL for use. Plated at 100. mu.L/well such that the final concentration of cells in each well is 3X 10 5 Per well. The corresponding peptide pools (peptide pools 1 to 5 prepared in example 3) were added in an amount of 10. mu.L/well, 3 duplicate wells per peptide pool, PHA (40. mu.g/mL) as a positive control well and Advanced RPMI 1640 medium as a negative control well, and 96-well ELISPOT plates were placed in a 5% CO-containing medium 2 The cell culture box is incubated at 37 ℃ for 12-48h, and the ELISPOT plate can not be moved in the period.
4. ELISpot assay mouse IFN- γ reaction points: the cells in the ELISPOT plate were gently removed and washed 5 times with PBS at 200. mu.L/well. R4-6A2 labeled monoclonal antibody (1mg/mL, Mouse IFN-. gamma.ELISpot) was treated with PBS containing 0.5% FBS PLUS kit (component of ALP) was diluted to a final concentration of 1. mu.g/mL, added to an ELISPOT plate in an amount of 100. mu.L/well, and incubated at room temperature for 2 h. PBS wash 5 times, 200 u L/hole. streptavidin-ALP (Mouse IFN-. gamma.ELISpot) was applied using PBS containing 0.5% FBS PLUS kit (component of ALP) was diluted 1:1000, added to an ELISPOT plate at 100. mu.L/well and incubated for 1h at room temperature. PBS wash 5 times, 200 u L/hole. The color developing solution was filtered using a 0.45 μm filter, and then an ELISPOT plate was added in an amount of 100. mu.L/well to observe the change of spots in the well. After the spots meet the requirements, quickly washing with a large amount of tap water, patting dry the water, and naturally drying the spots in dark. Reading the plate, scanning and counting the result.
5. The experimental results are as follows: as a result, 4 peptide pools Pool 1(P ═ 0.0002 and P) were found<0.0001), Pool 2(P ═ 0.0003 and P ═ 0.0002), Pool 3(P ═ 0.0147 and P ═ 0.0080), and Pool 4(P ═ 0.0310 and P ═ 0.0101) stimulate IFN- γ production by mouse splenocytes + The T lymphocyte counts were significantly higher in ATB mice than in LTBI and UC mice (fig. 3). Therefore, these peptide pools were selected for ROC curve analysis (fig. 4). 4 peptide pool induced IFN-gamma + Number of T lymphocytes ATB mice were selected from UC group mice (fig. 4, AUC 1, P<0.0001) or LTBI mice (AUC ═ 1, P)<0.0001), and LTBI mice can be further distinguished from UC mice (AUC 0.8229, P0.0073). Further analysis revealed that the sensitivity of the 4 peptide pools (Pool1, 2, 3 and 4) combined differential diagnosis of ATB vs UC, ATB vs LTBI and UC vs LTBI was 100%, 100% and 66.67%, respectively, and the specificity was 91.67% (Table 4).
TABLE 44 peptide pools for the combined diagnosis of sensitivity and specificity of ATB and LTBI
Figure BDA0003659180790000161
Wherein: AUC represents the area under the curve (area under the curve); p value represents a P value; 95% CI represents 95% confidence interval (95% confidence interval); cutoff value represents a Cutoff value (threshold); sensitivity represents Sensitivity; specificity indicates Specificity.
The receiver operating curve ROC for candidate diagnostic markers was plotted using software version GraphPad Pirsm 9.3.1 and statistically analyzed using the Wilson/Brown test. The stimulation data for each polypeptide was entered into the software and the analysis results included three parts: the first part is the ROC graph; the second part is the overall statistics including the AUC values and their 95% CI and P values; the third part is to show sensitivity and specificity, and to select the best CUTOFF value according to likelihood ratio.
Example 6 cytokine detection in ATB and LTBI mouse models
1. Preparation of spleen cell suspension: the procedure is as in example 5, step 1.
2. And (3) red blood cell lysis: the procedure is as in example 5, step 2.
3. Counting and paving: the procedure is as in example 5, step 3.
4. Luminex 200 detection of 17 cytokines in mice
The kit is adopted (Th1/Th2/Th9/Th17/Th22/Treg Cytokine 17-Plex Mouse procapraplex TM Panel) detects 17 cytokines (IFN-. gamma., IL-12p70, IL-13, IL-1. beta., IL-2, IL-4, IL-5, IL-6, TNF-. alpha., GM-CSF, IL-18, IL-10, IL-17A, IL-22, IL-23, IL-27, IL-9). The method comprises the following specific steps:
(1) dilution of reagents
Wash buffer (10X-1X): and (3) enabling the wash buffer with the volume of 10X to be as follows: ddH 2 Dilution to 1 × Wash Buffer at a ratio of 9: 1. Beads (50X-1X): vortex Beads (microspheres) for 30s, take 100. mu.L of each 50X Beads per tube, add 1X wash buffer to a final volume of 5mL, and mix well. Detection Antibody (50X-1X): 60 mu L of each 50X Detection Antibody (Detection Antibody) tube is taken out, and Detection Antibody dilution is added to the final volume of 3mL and mixed evenly to obtain 1X Detection Antibody mixed solution.
(2) Dissolution standard
Taking out the standard substance, and centrifuging at 2000 Xg for 10 s; adding 50. mu.L of Universal Assay Buffer to each standard tube; lightly mixing for 30 s; placing on ice for 5-10 min; the standards were mixed into one tube and Universal Assay Buffer was added to obtain 250. mu.L of mixed standard. See table 5 for standard configuration details.
TABLE 5 Standard configuration List
Standard substance number # Redissolution volume per tube Volume after dissolution Buffer addition volume Total volume
1 50μL 50μL 200μL 250μL
2 50μL 100μL 150μL 250μL
3 50μL 150μL 100μL 250μL
4 50μL 200μL 50μL 250μL
5 50μL 250μL 0μL 250μL
(3) Dilution of standards (4 times)
Taking out the PCR 8 union tube provided in the kit for diluting the standard substance; as shown in FIG. 5, 200. mu.L of the mixed standard was added to the first tube (tube 1) as standard 1; 150 μ L of Universal Assay Buffer was added to tubes 2-8, respectively; taking 50 mu L of mixed standard substance from the tube 1, adding the mixed standard substance into the tube 2, blowing and beating the mixed standard substance up and down for 10 times, and uniformly mixing the mixed standard substance and the tube to avoid the generation of bubbles as much as possible; and (3) replacing the gun head, sucking 50 mu L of the diluted standard substance from the tube 2, transferring the diluted standard substance into the tube 3, blowing and beating the diluted standard substance up and down for 10 times, and uniformly mixing. Transferring in sequence to complete gradient dilution of the mixed standard substance; placing on ice for standby.
(4) Preparing microspheres
Vortex microspheres for 30 s; to each well of a 96-well plate, 50 μ L of the pre-mixed microspheres were added. The 96-well plate was placed in a magnetic separator plate to ensure that the plate was firmly clamped. And standing the plate for 2min to allow the microspheres to settle. The magnetic plate was then quickly inverted and the liquid in the well plate was poured out. The 96-well plate cannot be taken out of the magnetic separation plate in the process; adding 150 mu L of 1X Wash Buffer into each hole, standing for 30s, then inverting the magnetic plate, and pouring out the liquid in the hole plate; in the inverted state, the residual liquid on the surface of the orifice plate was adsorbed with a paper towel.
(5) Incubation of microspheres with samples
Adding 50 μ L of sample or standard into the designated wells respectively; add 50. mu.L Universal Assay Buffer to the blank control; the plate was sealed, incubated with shaking at 500rpm for 30min at room temperature, and allowed to stand overnight at 4 ℃. The next day, the cells were removed and incubated at 500rpm with shaking at room temperature for 30 min.
(6) Washing plate
Placing the 96-well plate in a magnetic separation plate, and standing for 2 min; the sealing film is removed lightly to avoid splashing of liquid; inverting and removing the liquid in the pore plate; add 150. mu.L of 1 × Wash Buffer to each well, let stand for 30s, and remove the liquid from the well plate by inversion. Repeating the steps, and washing for 3 times; at the end of the last wash, the residual liquid was adsorbed with a paper towel.
(7) Adding detection antibody
Add 25 μ L of 1X detection antibody mix to each well; sealing the orifice plate with a new sealing film; the 96-well plate was removed from the magnetic separation plate and placed in a well plate shaker at 500rpm for 30min at room temperature.
(8) Washing plate
Placing the 96-well plate in a magnetic separation plate, and standing for 2 min; the sealing film is removed lightly to avoid splashing of liquid; inverting the liquid in the well plate to remove it; adding 150 mu L of 1X Wash Buffer into each hole, standing for 30s, inversely removing the liquid in the hole plate, and washing for 3 times; at the end of the last wash, the residual liquid was adsorbed with a paper towel.
(9) Addition of SA-PE
Add 50. mu.L of SA-PE to each well; sealing the orifice plate with a new sealing membrane; the 96-well plate was removed from the magnetic separation plate and placed in a well plate shaker at 500rpm for 30min at room temperature.
(10) Washing plate
Placing the 96-well plate in a magnetic separation plate, and standing for 2 min; the sealing film is removed lightly to avoid splashing of liquid; inverting the liquid in the well plate to remove it; adding 150 mu L of 1X Wash Buffer into each hole, standing for 30s, inversely removing the liquid in the hole plate, and washing for 3 times; at the end of the last wash, the residual liquid was adsorbed with a paper towel.
(11) On-machine detection
Add 120. mu.L Reading Buffer to each well; sealing the orifice plate with a new sealing membrane; taking the 96-well plate out of the magnetic separation plate, and placing the 96-well plate in a well plate oscillator to oscillate at the room temperature of 500rpm for 5 min; the sealing membrane was gently removed and placed in a Luminex 200 instrument for reading. And fitting the standard curve by adopting a five-parameter nonlinear regression mode to calculate a concentration value.
(12) Results of the experiment
To further elucidate the potential value of 5 peptide pools in the differential diagnosis of LTBI, ATB and UC mice, spleen cells from LTBI, ATB and UC mice were stimulated in vitro with peptide pools 1-5, respectively, and the expression levels of 17 cytokines in spleen cell culture supernatants were examined. To simplify and visualize the data, a P-value heatmap was plotted based on the differential P-values of cytokines induced by each peptide pool in the three groups (fig. 6). As a result, it was found that the levels of cytokines produced by splenocytes from mice in the 3 peptide pools (Pool1, Pool 2 and Pool 5) stimulated ATB, LTBI and UC groups were significantly different among the three groups (a in fig. 6, shown by white grid).
Specifically (B in fig. 6): (ii) for Pool of Pool1 peptides, its induced IL-2 levels are significantly higher in ATB mice than in LTBI (P ═ 0.0040) or lower than UC (P ═ 0.0285) group mice, and its induced IL-2 levels are significantly lower in LTBI group mice than in UC group (P ═ 0.0010); its induced TNF- α levels were significantly higher in ATB mice than in LTBI (P <0.0001) or UC (P ═ 0.0024) groups, and its induced TNF- α levels were significantly lower in LTBI groups than in UC groups (P ═ 0.0198); ② for Pool of Pool 2 peptides, its induced IL-6 levels were significantly lower in ATB mice than LTBI (P ═ 0.0252) or UC (P ═ 0.0054) groups of mice, and its induced IL-6 levels were significantly lower in LTBI groups of mice than UC groups (P ═ 0.0228); ③ for Pool of Pool 5 peptides, the induced TNF- α levels were significantly higher in ATB mice than in LTBI (P ═ 0.0141) and lower in UC group (P ═ 0.0187) and significantly lower in LTBI mice than in UC group (P ═ 0.0002).
Based on the above data, TNF- α cytokines were selected for ROC curve analysis (fig. 7 and table 6). The combined detection of levels of TNF- α induced by peptide pools Pool1 and Pool 5 distinguished LTBI mice from ATB group mice (fig. 7, AUC 1.000, P0.0039) and UC group mice (fig. 7, AUC 1.000, P0.0039), but did not distinguish ATB mice from UC group mice (AUC 0.5000, P > 0.9999). Further analysis revealed that the 2 peptide pools combined differential diagnosis of ATB vs LTBI and UC vs LTBI was 100% sensitive and 83.33% specific (Table 6).
TABLE 6 diagnosis of sensitivity and specificity of ATB and LTBI in combination with peptide Pool1 and Pool 5 induced cytokine TNF-alpha
Figure BDA0003659180790000191
In summary, the following steps:
(1) the invention discovers that 4 peptide pools Pool1, Pool 2, Pool 3 and Pool 4 stimulate IFN-gamma produced by splenocytes of mice for the first time + The T lymphocyte counts were significantly higher in ATB mice than in LTBI and UC mice. ROC curve analysis showed 4 peptide pools induced IFN-. gamma. + The number of T lymphocytes can distinguish ATB mice from UC group mice or LTBI mice, and can also distinguish LTBI mice from UC mice. Further analysis found that the sensitivity of the 4 peptide pools combined differential diagnosis of ATB vs UC, ATB vs LTBI and UC vs LTBI was 100%, 100% and 66.67%, respectively, and the specificity was 91.67%.
(2) The invention discovers that the cytokine levels produced by splenocytes of mice in groups of 3 peptide pools (Pool1, Pool 2 and Pool 5) stimulating ATB, LTBI and UC are remarkably different among three groups for the first time. Specifically, the method comprises the following steps: the Pool of Pool1 peptides induced IL-2 levels in ATB mice significantly above LTBI or below UC group mice, and their induced IL-2 levels in LTBI group mice were significantly below UC group; its induced TNF- α levels were significantly higher in ATB mice than in LTBI or UC groups, and its induced TNF- α levels were significantly lower in LTBI groups than in UC groups. Pool 2 peptides induced IL-6 levels significantly lower in ATB mice than in LTBI or UC groups, and induced IL-6 levels significantly lower in LTBI groups than in UC groups. The Pool of Pool 5 peptides induced TNF-. alpha.levels in ATB mice were significantly higher than in LTBI and lower than in UC group mice, and TNF-. alpha.levels in LTBI mice were significantly lower than in UC group. Based on the above data, TNF-. alpha.cytokines were selected for ROC curve analysis. The combined detection of the levels of TNF- α induced by peptide Pool1 and Pool 5 can distinguish LTBI mice from ATB and UC group mice, but cannot distinguish ATB mice from UC group mice. Further analysis shows that the sensitivity and the specificity of the 2 peptide pools combined differential diagnosis of ATB vs LTBI and UC vs LTBI are both 100% and 83.33%.
The present invention has been described in detail above. It will be apparent to those skilled in the art that the invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with reference to specific embodiments, it will be appreciated that the invention can be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The use of some of the essential features is possible within the scope of the claims attached below.
SEQUENCE LISTING
<110> eighth medical center of general hospital of people liberation force of China
<120> LTBI-RD related protein-based Th1 and CTL epitope peptide pool and application thereof
<160> 5
<170> PatentIn version 3.5
<210> 1
<211> 395
<212> PRT
<213> Mycobacterium tuberculosis
<400> 1
Met Arg Gly Gln Ala Ala Asn Leu Val Leu Ala Thr Trp Ile Ser Val
1 5 10 15
Val Asn Phe Trp Ala Trp Asn Leu Ile Gly Pro Leu Ser Thr Ser Tyr
20 25 30
Ala Arg Asp Met Ser Leu Ser Ser Ala Glu Ala Ser Leu Leu Val Ala
35 40 45
Thr Pro Ile Leu Val Gly Ala Leu Gly Arg Ile Val Thr Gly Pro Leu
50 55 60
Thr Asp Arg Phe Gly Gly Arg Ala Met Leu Ile Ala Val Thr Leu Ala
65 70 75 80
Ser Ile Leu Pro Val Leu Ala Val Gly Val Ala Ala Thr Met Gly Ser
85 90 95
Tyr Ala Leu Leu Val Phe Phe Gly Leu Phe Leu Gly Val Ala Gly Thr
100 105 110
Ile Phe Ala Val Gly Ile Pro Phe Ala Asn Asn Trp Tyr Gln Pro Ala
115 120 125
Arg Arg Gly Phe Ser Thr Gly Val Phe Gly Met Gly Met Val Gly Thr
130 135 140
Ala Leu Ser Ala Phe Phe Thr Pro Arg Phe Val Arg Trp Phe Gly Leu
145 150 155 160
Phe Thr Thr His Ala Ile Val Ala Ala Ala Leu Ala Ser Thr Ala Val
165 170 175
Val Ala Met Val Val Leu Arg Asp Ala Pro Tyr Phe Arg Pro Asn Ala
180 185 190
Asp Pro Val Leu Pro Arg Leu Lys Ala Ala Ala Arg Leu Pro Val Thr
195 200 205
Trp Glu Met Ser Phe Leu Tyr Ala Ile Val Phe Gly Gly Phe Val Ala
210 215 220
Phe Ser Asn Tyr Leu Pro Thr Tyr Ile Thr Thr Ile Tyr Gly Phe Ser
225 230 235 240
Thr Val Asp Ala Gly Ala Arg Thr Ala Gly Phe Ala Leu Ala Ala Val
245 250 255
Leu Ala Arg Pro Val Gly Gly Trp Leu Ser Asp Arg Ile Ala Pro Arg
260 265 270
His Val Val Leu Ala Ser Leu Ala Gly Thr Ala Leu Leu Ala Phe Ala
275 280 285
Ala Ala Leu Gln Pro Pro Pro Glu Val Trp Ser Ala Ala Thr Phe Ile
290 295 300
Thr Leu Ala Val Cys Leu Gly Val Gly Thr Gly Gly Val Phe Ala Trp
305 310 315 320
Val Ala Arg Arg Ala Pro Ala Ala Ser Val Gly Ser Val Thr Gly Ile
325 330 335
Val Ala Ala Ala Gly Gly Leu Gly Gly Tyr Phe Pro Pro Leu Val Met
340 345 350
Gly Ala Thr Tyr Asp Pro Val Asp Asn Asp Tyr Thr Val Gly Leu Leu
355 360 365
Leu Leu Val Ala Thr Ala Leu Val Ala Cys Thr Tyr Thr Ala Leu His
370 375 380
Ala Arg Glu Pro Val Ser Glu Glu Ala Ser Arg
385 390 395
<210> 2
<211> 144
<212> PRT
<213> Mycobacterium tuberculosis
<400> 2
Met Ala Thr Thr Leu Pro Val Gln Arg His Pro Arg Ser Leu Phe Pro
1 5 10 15
Glu Phe Ser Glu Leu Phe Ala Ala Phe Pro Ser Phe Ala Gly Leu Arg
20 25 30
Pro Thr Phe Asp Thr Arg Leu Met Arg Leu Glu Asp Glu Met Lys Glu
35 40 45
Gly Arg Tyr Glu Val Arg Ala Glu Leu Pro Gly Val Asp Pro Asp Lys
50 55 60
Asp Val Asp Ile Met Val Arg Asp Gly Gln Leu Thr Ile Lys Ala Glu
65 70 75 80
Arg Thr Glu Gln Lys Asp Phe Asp Gly Arg Ser Glu Phe Ala Tyr Gly
85 90 95
Ser Phe Val Arg Thr Val Ser Leu Pro Val Gly Ala Asp Glu Asp Asp
100 105 110
Ile Lys Ala Thr Tyr Asp Lys Gly Ile Leu Thr Val Ser Val Ala Val
115 120 125
Ser Glu Gly Lys Pro Thr Glu Lys His Ile Gln Ile Arg Ser Thr Asn
130 135 140
<210> 3
<211> 143
<212> PRT
<213> Mycobacterium tuberculosis
<400> 3
Met Thr Thr Ala Arg Asp Ile Met Asn Ala Gly Val Thr Cys Val Gly
1 5 10 15
Glu His Glu Thr Leu Thr Ala Ala Ala Gln Tyr Met Arg Glu His Asp
20 25 30
Ile Gly Ala Leu Pro Ile Cys Gly Asp Asp Asp Arg Leu His Gly Met
35 40 45
Leu Thr Asp Arg Asp Ile Val Ile Lys Gly Leu Ala Ala Gly Leu Asp
50 55 60
Pro Asn Thr Ala Thr Ala Gly Glu Leu Ala Arg Asp Ser Ile Tyr Tyr
65 70 75 80
Val Asp Ala Asn Ala Ser Ile Gln Glu Met Leu Asn Val Met Glu Glu
85 90 95
His Gln Val Arg Arg Val Pro Val Ile Ser Glu His Arg Leu Val Gly
100 105 110
Ile Val Thr Glu Ala Asp Ile Ala Arg His Leu Pro Glu His Ala Ile
115 120 125
Val Gln Phe Val Lys Ala Ile Cys Ser Pro Met Ala Leu Ala Ser
130 135 140
<210> 4
<211> 375
<212> PRT
<213> Mycobacterium tuberculosis
<400> 4
Val Thr Gln Thr Gly Lys Arg Gln Arg Arg Lys Phe Gly Arg Ile Arg
1 5 10 15
Gln Phe Asn Ser Gly Arg Trp Gln Ala Ser Tyr Thr Gly Pro Asp Gly
20 25 30
Arg Val Tyr Ile Ala Pro Lys Thr Phe Asn Ala Lys Ile Asp Ala Glu
35 40 45
Ala Trp Leu Thr Asp Arg Arg Arg Glu Ile Asp Arg Gln Leu Trp Ser
50 55 60
Pro Ala Ser Gly Gln Glu Asp Arg Pro Gly Ala Pro Phe Gly Glu Tyr
65 70 75 80
Ala Glu Gly Trp Leu Lys Gln Arg Gly Ile Lys Asp Arg Thr Arg Ala
85 90 95
His Tyr Arg Lys Leu Leu Asp Asn His Ile Leu Ala Thr Phe Ala Asp
100 105 110
Thr Asp Leu Arg Asp Ile Thr Pro Ala Ala Val Arg Arg Trp Tyr Ala
115 120 125
Thr Thr Ala Val Gly Thr Pro Thr Met Arg Ala His Ser Tyr Ser Leu
130 135 140
Leu Arg Ala Ile Met Gln Thr Ala Leu Ala Asp Asp Leu Ile Asp Ser
145 150 155 160
Asn Pro Cys Arg Ile Ser Gly Ala Ser Thr Ala Arg Arg Val His Lys
165 170 175
Ile Arg Pro Ala Thr Leu Asp Glu Leu Glu Thr Ile Thr Lys Ala Met
180 185 190
Pro Asp Pro Tyr Gln Ala Phe Val Leu Met Ala Ala Trp Leu Ala Met
195 200 205
Arg Tyr Gly Glu Leu Thr Glu Leu Arg Arg Lys Asp Ile Asp Leu His
210 215 220
Gly Glu Val Ala Arg Val Arg Arg Ala Val Val Arg Val Gly Glu Gly
225 230 235 240
Phe Lys Val Thr Thr Pro Lys Ser Asp Ala Gly Val Arg Asp Ile Ser
245 250 255
Ile Pro Pro His Leu Ile Pro Ala Ile Glu Asp His Leu His Lys His
260 265 270
Val Asn Pro Gly Arg Glu Ser Leu Leu Phe Pro Ser Val Asn Asp Pro
275 280 285
Asn Arg His Leu Ala Pro Ser Ala Leu Tyr Arg Met Phe Tyr Lys Ala
290 295 300
Arg Lys Ala Ala Gly Arg Pro Asp Leu Arg Val His Asp Leu Arg His
305 310 315 320
Ser Gly Ala Val Leu Ala Ala Ser Thr Gly Ala Thr Leu Ala Glu Leu
325 330 335
Met Gln Arg Leu Gly His Ser Thr Ala Gly Ala Ala Leu Arg Tyr Gln
340 345 350
His Ala Ala Lys Gly Arg Asp Arg Glu Ile Ala Ala Leu Leu Ser Lys
355 360 365
Leu Ala Glu Asn Gln Glu Met
370 375
<210> 5
<211> 75
<212> PRT
<213> Mycobacterium tuberculosis
<400> 5
Val Ile Ala Gly Val Asp Gln Ala Leu Ala Ala Thr Gly Gln Ala Ser
1 5 10 15
Gln Arg Ala Ala Gly Ala Ser Gly Gly Val Thr Val Gly Val Gly Val
20 25 30
Gly Thr Glu Gln Arg Asn Leu Ser Val Val Ala Pro Ser Gln Phe Thr
35 40 45
Phe Ser Ser Arg Ser Pro Asp Phe Val Asp Glu Thr Ala Gly Gln Ser
50 55 60
Trp Cys Ala Ile Leu Gly Leu Asn Gln Phe His
65 70 75

Claims (6)

1. A polypeptide composition, wherein said polypeptide composition is any one of:
A1) the polypeptide composition consists of polypeptides with the amino acid sequences of 162-176 th position of SEQ ID No.1, 193-207 th position of SEQ ID No.1, 268-276 th position of SEQ ID No.1 and 378-386 th position of SEQ ID No. 1;
A2) the polypeptide composition consists of polypeptides with amino acid sequences of 95 th to 109 th of SEQ ID No.2, 92 th to 106 th of SEQ ID No.2, 23 th to 31 th of SEQ ID No.2 and 92 th to 100 th of SEQ ID No. 2;
A3) the polypeptide composition consists of polypeptides with the amino acid sequences of 42 th-56 th position of SEQ ID No.3, 128 th-142 th position of SEQ ID No.3, 133 th-141 th position of SEQ ID No.3 and 131 th-139 th position of SEQ ID No. 3;
A4) the polypeptide composition consists of polypeptides with the amino acid sequences of 294-308 th position of SEQ ID No.4, 296-310 th position of SEQ ID No.4, 202-210 th position of SEQ ID No.4 and 325-333 th position of SEQ ID No. 4;
A5) the polypeptide composition consists of polypeptides with amino acid sequences of 2-16 th position of SEQ ID No.5, 16-30 th position of SEQ ID No.5, 47-56 th position of SEQ ID No.5 and 41-49 th position of SEQ ID No. 5;
A6) the polypeptide composition consists of polypeptides with the amino acid sequences of 162-176 th position of SEQ ID No.1, 193-207 th position of SEQ ID No.1, 268-276 th position of SEQ ID No.1, 378-386 th position of SEQ ID No.1, 2-16 th position of SEQ ID No.5, 16-30 th position of SEQ ID No.5, 47-56 th position of SEQ ID No.5 and 41-49 th position of SEQ ID No. 5;
A7) the polypeptide composition consists of polypeptides with the amino acid sequences of 162-176 position of SEQ ID No.1, 193-207 position of SEQ ID No.1, 268-276 position of SEQ ID No.1, 378-386 position of SEQ ID No.1, 95-109 position of SEQ ID No.2, 92-106 position of SEQ ID No.2, 23-31 position of SEQ ID No.2, 92-100 position of SEQ ID No.2, 42-56 position of SEQ ID No.3, 128-142 position of SEQ ID No.3, 133-141 position of SEQ ID No.3, 131-139 position of SEQ ID No.3, 294-308 position of SEQ ID No.4, 296-310 position of SEQ ID No.4, 202-210 position of SEQ ID No.4 and 325-333 position of SEQ ID No. 4.
2. The polypeptide composition of claim 1 for use in any one of:
B1) use in the diagnosis and/or identification of diseases caused by mycobacterium tuberculosis;
B2) use in the manufacture of a product for the diagnosis and/or identification of diseases caused by mycobacterium tuberculosis;
B3) the application in distinguishing active tuberculosis patients and latent tuberculosis infected patients;
B4) the application in preparing products for distinguishing active tuberculosis patients and latent tuberculosis infectors;
B5) the application in diagnosing latent tuberculosis infection or preparing products for diagnosing latent tuberculosis infection;
B6) use in the identification of healthy subjects and patients with active tuberculosis;
B7) use in the manufacture of a product for the differential discrimination between healthy subjects and patients with active tuberculosis;
B8) use in the identification of healthy subjects and latent tuberculosis infected persons;
B9) the application in preparing products for distinguishing healthy subjects from latent tuberculosis infected persons;
B10) application in preparing tuberculosis vaccine.
3. The use according to claim 2, wherein the disease caused by mycobacterium tuberculosis is tuberculosis.
4. Use according to claim 3, wherein the tuberculosis is active tuberculosis or latent tuberculosis infection.
5. A kit for identifying a latent tuberculosis infection from active tuberculosis, said kit comprising any one of the polypeptide compositions of claim 1.
6. The kit of claim 5, wherein the kit further comprises a detection reagent for IFN- γ.
CN202210568272.6A 2022-05-24 Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof Active CN115028695B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210568272.6A CN115028695B (en) 2022-05-24 Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210568272.6A CN115028695B (en) 2022-05-24 Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof

Publications (2)

Publication Number Publication Date
CN115028695A true CN115028695A (en) 2022-09-09
CN115028695B CN115028695B (en) 2024-05-17

Family

ID=

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203239A (en) * 2005-03-31 2008-06-18 莱顿大学医药中心 Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
US20090123492A1 (en) * 2007-11-13 2009-05-14 Mario Alberto Flores-Valdez Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state
CN104387449A (en) * 2014-10-29 2015-03-04 南方医科大学 Mycobacterium tuberculosis specific CD8<+>T cell epitope peptide P29 and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203239A (en) * 2005-03-31 2008-06-18 莱顿大学医药中心 Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
US20090123492A1 (en) * 2007-11-13 2009-05-14 Mario Alberto Flores-Valdez Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state
CN104387449A (en) * 2014-10-29 2015-03-04 南方医科大学 Mycobacterium tuberculosis specific CD8<+>T cell epitope peptide P29 and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴启航;李海波;赵隆麒;王心倩;孙妍;余晓丽;: "结核分枝杆菌Rv3841中B、CTL及Th细胞表位预测", 武汉轻工大学学报, no. 04, 15 December 2017 (2017-12-15), pages 22 - 27 *

Similar Documents

Publication Publication Date Title
CN102004155B (en) Kit and method for detecting mycobacterium tuberculosis infection and application
Simsek et al. Comparison of tuberculin skin testing and T-SPOT. TB for diagnosis of latent and active tuberculosis
US9146236B2 (en) Methods for differentiating between disease states
WO2016095273A1 (en) Antigen stimulant for detecting mycobacterium tuberculosis infection, kit, and applications of antigen stimulant
CN107076744B (en) Composition for diagnosing latent infection of mycobacterium tuberculosis
CN107216373B (en) Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application thereof
CN102608333B (en) Tuberculosis diagnostic composition and application thereof
CN107011418B (en) Antigen polypeptide pool for detecting mycobacterium tuberculosis infection and application thereof
WO2005090988A2 (en) Mycobacterium tuberculosis infection diagnostic test
Ott et al. CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases
CN114907460B (en) Mycobacterium tuberculosis LTBI-RD related protein antigen Th1 epitope peptide and application thereof
CN106248934B (en) Antigen of mycobacterium tuberculosis albumen Rv0446c and its t cell epitope peptide application
Gong et al. Prediction of Th1 and cytotoxic T lymphocyte epitopes of Mycobacterium tuberculosis and evaluation of their potential in the diagnosis of tuberculosis in a mouse model and in humans
CN106939035B (en) Mycobacterium tuberculosis T cell epitope polypeptide and application thereof
DK2872896T3 (en) Status of a tuberculosis infection in an individual
CN106405107B (en) Antigen of mycobacterium tuberculosis albumen Rv2941 and its t cell epitope peptide application
KR102305770B1 (en) Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
Nagai et al. Immunological responses and epitope mapping by tuberculosis-associated antigens within the RD1 region in Japanese patients
CN109991417B (en) Immune marker for tuberculosis and application
CN115028695B (en) Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof
CN115028695A (en) Th1 and CTL epitope peptide pool based on LTBI-RD related protein and application thereof
CN114736276B (en) CTL epitope peptide of mycobacterium tuberculosis LTBI-RD related protein antigen and application thereof
CN114671928A (en) Application of mycobacterium tuberculosis T cell epitope protein Rv1566c-444
CN106248936B (en) The application of antigen of mycobacterium tuberculosis albumen Rv2201 and its t cell epitope peptide
Liu et al. Prediction and identification of CD4+ T cell epitope for the protective antigens of Mycobacterium tuberculosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant